---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-073419"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2026-06-12T20:05:21+00:00"
generated_at: "2026-06-12T20:10:48.881258+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma annual meeting elects director; proxy share count corrected

## Summary
- Proxy mistakenly stated 27,668,036 shares outstanding; correct count is 26,614,628.
- Quorum of 60.8% (16,193,686 shares) present at June 11, 2026 annual meeting.
- Ron Bentsur elected Class I director with 8,354,838 votes for, 391,265 against.
- Kesselman & Kesselman ratified as independent auditor for FY2026 (15,662,222 for).

## SEC filing metadata
- accession: 0001104659-26-073419
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2026-06-12T20:05:21+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/0001104659-26-073419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/tm2617533d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-073419
- JSON: https://secwatch.observer/filing/0001104659-26-073419.json
- Plain text: https://secwatch.observer/filing/0001104659-26-073419.txt

## Key facts
- Shareholder Votes
  Nuvectis Pharma, Inc. shareholders approved Election of Class I director to hold office until the 2029 annual meeting at the 2026-06-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The vote with respect to the election of the Class I director to hold office until the 2029 annual meeting was as follows: Director Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes Ron Bentsur 8,354,838 391,265 216 7,447,367
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/0001104659-26-073419-index.htm
- Shareholder Votes
  Nuvectis Pharma, Inc. shareholders approved Ratification of Kesselman & Kesselman as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was as follows: Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes 15,662,222 10,574 520,890 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/0001104659-26-073419-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.